hepat
c
viru
hcv
major
caus
agent
sever
liver
diseas
includ
fibrosi
cirrhosi
liver
cancer
therapi
improv
year
continu
associ
advers
side
effect
variabl
success
rate
furthermor
vaccin
protect
hcv
infect
remain
elus
develop
effect
intervent
measur
delay
lack
suitabl
anim
model
natur
hcv
infect
human
chimpanze
determin
limit
host
rang
poorli
understood
part
due
difficulti
studi
hcv
cell
cultur
progress
made
elucid
barrier
hcv
lifecycl
nonpermiss
speci
help
futur
construct
anim
model
hcv
infect
immun
pathogenesi
hepat
c
viru
hcv
positivesens
singl
strand
rna
viru
classifi
within
hepaciviru
genu
flavivirida
famili
hcv
high
propens
establish
lifelong
persist
infect
associ
signific
risk
progress
liver
fibrosi
hepatocellular
carcinoma
worldwid
least
million
peopl
chronic
infect
result
estim
death
due
cirrhosi
cancer
annual
perz
et
al
epidemiolog
data
incomplet
unit
state
alon
frequenc
chronic
carrier
may
twice
high
edlin
thu
hcv
pose
major
public
health
threat
treatment
option
improv
still
limit
furthermor
current
standard
care
consist
combin
pegyl
interferon
ifn
alpha
nucleosid
analog
ribavirin
rbv
one
two
hcv
proteas
inhibitor
boceprevir
telaprevir
well
toler
prior
approv
directli
act
antivir
daa
roughli
genotyp
infect
patient
clinic
hardest
hcv
substrain
treat
underw
treatment
clear
infect
inclus
hcv
proteas
inhibitor
pegifnrbv
regiment
increas
sustain
virolog
respons
svr
rate
certain
clinic
trial
cohort
kwo
et
al
mchutchison
et
al
poordad
et
al
current
numer
viral
host
protein
pursu
antivir
drug
target
secondgener
proteas
inhibitor
sever
compound
interf
function
phosphoprotein
rnadepend
rna
polymeras
alreadi
test
clinic
trial
yang
et
al
combin
oral
administ
daa
distinct
mechan
action
hold
promis
boost
svr
rate
across
hcv
patient
cohort
despit
success
unexpect
toxic
latestag
clinic
trial
led
discontinu
delay
develop
potent
compound
includ
proteas
inhibitor
lamarr
et
al
nucleotid
polymeras
inhibitor
vernachio
et
al
cyclophilin
antagonist
alisporivir
coelmont
et
al
challeng
highlight
need
thorough
preclin
test
predict
anim
model
likewis
develop
pangenotyp
prophylact
therapeut
vaccin
instrument
contain
hcv
epidem
resourcepoor
commun
would
greatli
acceler
tractabl
anim
model
chimpanze
avail
immunocompet
vivo
experiment
system
use
limit
ethic
concern
restrict
avail
prohibit
high
cost
undoubtedli
tangibl
anim
model
need
priorit
clinic
develop
vaccin
drug
candid
also
gain
deeper
insight
virushost
biolog
studi
hcv
convent
cell
cultur
system
ie
human
hepatoma
cell
may
accur
reflect
host
respons
infect
advent
sensit
detect
method
viral
infect
improv
technic
abil
cultur
primari
hepatocyt
possibl
dissect
hcv
infect
physiologicalrelev
environ
jone
et
al
ploss
et
al
howev
even
advanc
tissu
cultur
platform
includ
micropattern
primari
hepatocyt
cocultur
mpcc
jone
et
al
khetani
bhatia
ploss
et
al
cultur
human
fetal
hepatocyt
marukian
et
al
hepatocytelik
cell
deriv
induc
pluripotentstem
cell
ipsc
roelandt
et
al
schwartz
et
al
wu
et
al
import
featur
liver
biolog
yet
adequ
recapitul
within
liver
numer
cell
type
includ
hepatocyt
variou
nonparenchym
cell
subset
ie
liver
sinusoid
endotheli
cell
stellat
cell
oval
cell
arrang
intric
threedimension
architectur
nutrient
oxygen
gradient
within
liver
result
compartment
liver
refer
zonat
affect
metabol
detoxif
respons
injuri
whether
specif
microenviron
impact
hcv
infect
understood
may
adequ
model
within
threedimension
context
liver
furthermor
tractabl
anim
model
may
suitabl
deciph
mechan
viral
persist
pathogenesi
assess
diseas
state
comorbid
hiv
alcohol
nutrit
exacerb
viral
hepat
extrahepat
manifest
associ
hcv
infect
host
known
natur
permiss
hcv
infect
human
chimpanze
tabl
basi
limit
speci
tropism
incomplet
understood
topic
review
chimpanze
model
play
instrument
role
earli
character
nona
nonb
hepat
houghton
ultim
led
discoveri
hcv
etiolog
agent
classic
defin
nona
nonb
hepat
michael
houghton
team
choo
et
al
subsequ
mani
import
discoveri
facilit
use
exampl
first
demonstr
chimpanze
vitro
transcrib
rna
hcv
cdna
clone
infecti
kolykhalov
et
al
furthermor
experiment
infect
chimpanze
hcv
help
defin
natur
protect
immun
farci
et
al
princ
et
al
demonstr
signific
cellular
subset
stringent
role
cell
control
chronic
hcv
infect
shoukri
et
al
chimpanze
remain
fulli
immunocompet
anim
model
hcv
infect
consequ
continu
play
import
role
evalu
preclin
efficaci
vaccin
candid
review
houghton
preced
efficaci
new
treatment
modal
ifnfre
control
hcv
infect
daa
olsen
et
al
interfer
liver
specif
microrna
mir
lanford
et
al
first
shown
chimpanze
despit
util
use
larg
ape
biomed
research
rais
ethic
concern
culmin
ban
experi
conduct
chimpanze
mani
countri
nih
moratorium
nonessenti
chimpanze
research
nih
like
constrain
hcv
research
futur
made
need
altern
anim
model
even
press
natur
host
reservoir
hcv
remain
poorli
defin
chimpanze
experiment
infect
hcv
preval
chimpanze
great
ape
gorilla
orangutan
wild
known
search
altern
readili
access
experiment
model
hcv
numer
speci
test
suscept
hcv
woodchuck
oldand
newworld
monkey
includ
cynomolgu
rhesu
japanes
green
monkey
doguera
abe
et
al
chacma
baboon
sitheb
et
al
cottontop
tamarin
garson
et
al
marmoset
appear
mostli
resist
hcv
infect
surprisingli
tree
shrew
tupaia
belangeri
distantli
relat
primat
schmitz
et
al
xu
et
al
appear
support
hcv
infect
level
xie
et
al
xu
et
al
tabl
recent
shown
develop
sign
sever
liver
diseas
includ
steatosi
fibrosi
cirrhosi
amako
et
al
data
encourag
addit
studi
larger
cohort
outbr
thu
genet
heterogen
speci
need
defin
clearli
natur
cours
hcv
infect
tree
shrew
genet
relat
virus
replic
readili
nonhuman
speci
consid
potenti
surrog
studi
hcv
vivo
promin
gb
virus
gbv
name
surgeon
georg
baber
gb
present
acut
viral
hepat
deinhardt
et
al
specif
gbvb
transmit
new
world
monkey
bukh
et
al
karayianni
et
al
lanford
et
al
schalud
et
al
simon
et
al
gbvb
hcv
belong
flavivirida
famili
share
approxim
amino
acid
ident
within
polyprotein
constrain
util
model
test
drug
specif
hcv
vaccin
candid
formul
hcv
specif
antigen
anoth
caveat
differ
cours
gbvb
infect
tamarin
marmoset
result
acut
hepat
butin
contrast
hcv
establish
chronic
recent
virus
genet
relat
hcv
gbvb
detect
speci
nonprim
hepaciviru
nphv
also
known
canin
hepaciviru
chv
identifi
dog
kapoor
et
al
hors
burbelo
et
al
intriguingli
chvnphv
appear
broader
tissu
tropism
speci
yet
shown
caus
hepat
compar
analysi
chvnphv
hcv
may
help
shed
light
potenti
common
viral
host
factor
determin
viral
host
tissu
tropism
sinc
hcv
readili
replic
nonhuman
speci
conceptu
straightforward
strategi
would
introduc
relev
tissu
compart
human
liverinto
mice
end
variou
approach
taken
includ
transplant
human
liver
piec
kidney
capsul
ilan
et
al
engraft
human
ectop
artifici
liver
heal
periton
caviti
chen
et
al
actual
expans
human
hepatocyt
within
liver
parenchyma
review
de
jong
et
al
meuleman
lerouxroel
immunocompromis
mice
latter
approach
suitabl
xenorecipi
combin
two
featur
immunodefici
prevent
graft
reject
liver
injuri
provid
growth
stimulu
normal
quiescent
hepatocyt
well
yield
transplant
human
cell
competit
growth
advantag
endogen
murin
cell
bestcharacter
liver
injuri
mous
strain
urokinasetyp
plasminogen
activ
upa
transgen
mice
heckel
et
al
mice
defici
fumaryl
acetoacet
hydrolas
fah
gromp
et
al
cross
immunodefici
background
liver
either
line
highli
repopul
human
hepatocyt
render
human
liver
chimer
mice
suscept
hcv
infect
bissig
et
al
mercer
et
al
meuleman
et
al
human
mice
invalu
studi
basic
aspect
hcv
biolog
within
threedimension
context
liver
assess
preclin
efficaci
antivir
compound
biolog
review
meuleman
lerouxroel
howev
presum
due
immunocompromis
statu
hcv
infect
human
liver
chimer
mice
gener
exhibit
sign
progress
liver
diseas
process
thought
immunemedi
human
overcom
caveat
engraft
compon
human
immun
system
alongsid
human
hepatocyt
singl
recipi
propos
legrand
et
al
proofofconcept
strategi
provid
recent
studi
show
mice
coinject
mixtur
human
hematopoiet
stem
cell
fetal
hepatoblast
nonparenchym
cell
could
infect
hcv
develop
sign
liver
fibrosi
washburn
et
al
intrigu
human
immun
respons
gener
weak
reconstitut
mice
addit
modif
need
improv
cellular
complex
function
engraft
human
immun
system
review
shultz
et
al
willing
et
al
util
xenotransplant
model
hamper
low
throughput
intric
logist
high
cost
technic
difficulti
product
also
inher
donortodonor
variabl
differ
human
chimer
anim
inbr
mous
model
hcv
would
overcom
technic
difficulti
xenotransplant
model
mice
inherit
suscept
hcv
could
produc
fairli
easili
larg
quantiti
would
amend
genet
manipul
defin
genet
background
viral
infect
could
analyz
vast
amount
exist
tool
reagent
challeng
elucid
overcom
restrict
hcv
complet
lifecycl
mous
cell
mice
fig
recent
year
progress
made
explain
aspect
restrict
host
rang
hcv
follow
section
highlight
barrier
hcv
lifecycl
nonpermiss
speci
focus
mice
discuss
put
strategi
overcom
larg
number
cellular
factor
implic
facilit
hcv
entri
human
cell
coordin
multistep
process
tabl
review
ploss
evan
hcv
complex
host
lipoprotein
call
lipoviroparticl
thought
initi
attach
glycosaminoglycan
bind
lowdens
lipoprotein
receptor
ldlr
scaveng
receptor
class
b
type
scarselli
et
al
tetraspanin
pileri
et
al
hepatocyt
surfac
engag
tight
junction
protein
evan
et
al
occludin
ocln
liu
et
al
ploss
et
al
ultim
result
endocytot
uptak
fig
recent
receptor
tyrosin
kinas
epiderm
growth
factor
receptor
egfr
ephrin
receptor
lupberg
et
al
cholesterol
uptak
receptor
niemannpick
like
sainz
et
al
implic
viral
entri
process
indirectli
influenc
composit
membran
microdomain
ctype
lectin
liverlymph
nodespecif
intercellular
adhes
integrin
lsign
cormier
et
al
express
liver
sinusoid
endotheli
cell
lsec
dendrit
cellspecif
intercellular
adhes
nonintegrin
dcsign
express
dendrit
kupffer
cell
shown
bind
hcv
gardner
et
al
lozach
et
al
pohlmann
et
al
ctype
lectin
sinusoid
cell
may
abl
trap
hcv
liver
known
whether
lead
product
infect
hepatocyt
tran
whether
sequest
hcv
subject
lysosom
degrad
molecul
meerten
et
al
zheng
et
al
transferrin
receptor
tfr
martin
uprichard
protocadherin
wongstaal
et
al
propos
involv
influenc
hcv
entri
howev
express
appreci
level
liver
tabl
thu
strong
experiment
evid
support
suggest
relev
viral
entri
independ
confirm
result
still
remain
pend
contrast
human
hepatocyt
murin
cell
support
hcv
entri
therebi
creat
first
import
barrier
broader
host
tropism
viru
attempt
defin
determin
restrict
hcv
entri
nonhuman
cell
cdna
complement
screen
conduct
mous
cell
ectop
express
human
human
ocln
identifi
miss
factor
need
facilit
viral
entri
human
mous
cell
ocln
requir
ocln
need
human
origin
promot
viral
entri
mous
lymph
node
liver
placenta
lymph
node
spleen
pancrea
gardner
et
al
cell
observ
line
previou
report
demonstr
contrast
variou
nonhuman
primat
speci
mous
support
hcv
pseudoparticl
entri
human
hepatoma
cell
lack
endogen
express
flint
et
al
similarli
human
cell
lack
endogen
ocln
express
primat
sequenc
function
equival
human
ocln
wherea
canin
hamster
mous
rat
ocln
intermedi
low
activ
guinea
pig
ocln
complet
nonfunct
michta
et
al
ocln
differ
second
extracellular
loop
part
respons
appar
function
activ
contrast
residu
within
first
extracellular
loop
requir
hcv
entri
evan
et
al
conserv
mice
man
thu
surpris
mous
support
hcv
uptak
origin
shown
human
mous
bind
solubl
hcv
scarselli
et
al
nonetheless
vitro
vivo
dorner
et
al
infect
assay
mous
human
equal
function
appar
conflict
data
like
attribut
readout
system
highlight
hcv
bind
may
reliabl
proxi
function
entri
assay
date
differ
suscept
cell
nonhuman
origin
hcv
entri
larg
account
differ
critic
posit
within
respect
orthologu
ocln
limit
absent
express
observ
ocln
compris
minim
set
human
factor
requir
render
mous
cell
permiss
hcv
entri
vitro
provid
blue
print
engin
mous
least
support
viral
uptak
vivo
genet
human
mice
success
construct
express
receptor
andor
coreceptor
mice
human
pathogen
polioviru
racaniello
ren
measl
viru
sellin
horvat
human
coronaviru
lassnig
et
al
human
immunodefici
viru
klotman
notkin
listeria
monocytogen
lecuit
et
al
earlier
attempt
render
mice
suscept
hcv
infect
transgen
express
success
masciopinto
et
al
express
human
wide
varieti
tissu
increas
bind
recombin
liver
thymocyt
splenic
lymphocyt
comparison
nontransgen
control
due
lack
human
ocln
human
mice
resist
hcv
infect
recent
demonstr
adenovir
deliveri
human
ocln
suffici
allow
hcv
infect
fullyimmunocompet
inbr
mice
dorner
et
al
use
intergenotyp
viru
chimera
express
cre
recombinas
activ
cellular
report
vivo
uptak
divers
hcv
genotyp
could
conveni
quantifi
bioluminesc
imag
util
block
antibodi
specif
viral
envelop
protein
express
entri
factor
mutant
mice
target
disrupt
gene
valid
uptak
hcv
murin
hepatocyt
hcv
glycoproteinmedi
fashion
furthermor
establish
preced
appli
mous
genet
dissect
viral
entri
process
addit
valid
role
hcv
uptak
vivo
first
time
beyond
studi
hcv
entri
model
employ
evalu
passiv
activ
immun
strategi
dorner
et
al
press
giang
et
al
transient
adenovir
deliveri
approach
highthroughput
allow
rapid
evalu
mutant
gene
howev
order
accur
reproduc
complex
process
hcv
entri
vivo
import
achiev
nativ
express
pattern
human
hcv
entri
factor
orthologu
use
transgen
andor
knockin
approach
recent
transgen
mice
express
human
ocln
gener
appear
permiss
hcv
infect
vivo
hikosaka
et
al
appar
discrep
transient
adenovir
stabl
transgen
express
approach
part
explain
lower
level
entri
factor
express
transgen
mice
requir
sensit
report
system
quantifi
viral
entri
dorner
et
al
altern
host
adapt
approach
overcom
speci
barrier
may
possibl
adapt
hcv
usag
entri
factor
ortholog
speci
use
unbias
select
approach
laboratori
strain
hcv
adapt
util
mous
bitzegeio
et
al
take
advantag
high
mutat
plastic
hcv
three
adapt
mutat
viral
glycoprotein
identifi
allow
viru
enter
cell
express
human
ocln
mous
interestingli
result
murinetrop
mt
hcv
also
capabl
effici
util
mous
ocln
lower
depend
whether
mthcv
capabl
infect
mous
hepatocyt
vitro
vivo
yet
shown
clearli
studi
provid
import
proofofconcept
valid
viral
adapt
approach
also
rais
potenti
caveat
adapt
mutat
within
viral
envelop
appear
result
conform
chang
consequ
remain
test
whether
mthcv
faith
recapitul
viral
entri
rais
concern
whether
neutral
capac
antibodi
human
specif
therapeut
block
hcv
entri
adequ
test
contribut
host
factor
implic
viral
entri
speci
tropism
hcv
well
understood
human
murin
orthologu
share
high
degre
amino
acid
sequenc
similar
tabl
discuss
differ
individu
residu
drastic
affect
viral
uptak
effici
exact
role
egf
receptor
ephrin
receptor
express
mous
human
hepatocyt
process
incomplet
defin
receptor
tyrosin
kinas
rtk
appear
mediat
entri
regul
coreceptor
associ
viral
glycoproteindepend
membran
fusion
lupberg
et
al
recent
shown
egfr
activ
depend
interact
hcv
diao
et
al
although
conceiv
express
human
egfr
andor
ephrin
receptor
could
increas
hcv
entri
effici
vivo
murin
orthologu
appear
exert
suffici
function
genet
human
mice
interestingli
although
shown
play
role
viral
entri
human
cell
vitro
vivo
sainz
et
al
appear
dispens
entri
mous
cell
contrast
human
murin
ortholog
approxim
sequenc
similar
human
protein
abundantli
express
gut
liver
altmann
et
al
nonetheless
hcv
still
capabl
enter
hepatocyt
mice
modifi
express
combin
human
ocln
dorner
et
al
suggest
level
redund
process
conceiv
hcv
entri
would
affect
perhap
becom
effici
along
human
ocln
ectop
coexpress
liver
remain
experiment
test
recent
demonstr
hepat
overexpress
human
transgen
mice
temel
et
al
via
adenovir
deliveri
modul
cellular
plasma
lipid
metabol
kurano
et
al
alter
cellular
lipid
profil
arguabl
affect
composit
membran
microdomain
consequ
traffick
membran
protein
includ
hcv
entri
factor
follow
receptor
mediat
endocytosi
viral
membran
fuse
endosom
eventu
releas
hcv
rna
genom
nucleocapsid
cytoplasm
known
viral
rna
translat
occur
vivo
rna
directli
introduc
mous
hepatocyt
eg
hydrodynam
deliveri
mccaffrey
et
al
suggest
hcv
intern
ribosom
entri
site
ire
within
untransl
region
function
mous
cell
recent
genet
human
mous
model
construct
util
cell
cultur
produc
recombin
hepat
c
viru
activ
cellular
encod
report
dorner
et
al
press
model
hcv
taken
murin
hepatocyt
viral
glycoproteindepend
fashion
provid
evid
fusion
uncoat
work
effici
background
advent
hcv
replicon
ie
subgenom
fulllength
genom
contain
domin
select
marker
neomycin
amino
transferas
blight
et
al
lohmann
et
al
allow
assess
whether
hcv
capabl
replic
nonhuman
cell
inde
replicon
introduc
mous
hepatoma
cell
line
embryon
fibroblast
cell
clone
harbor
replic
hcv
rna
could
identifi
low
frequenc
uprichard
et
al
zhu
et
al
data
suggest
necessari
host
factor
present
mous
cell
suffici
similar
support
hcv
rna
replic
howev
conceiv
viral
rna
replic
machineri
cooper
robustli
essenti
human
host
factor
murin
counterpart
target
genom
wide
loss
function
screen
led
discoveri
numer
cellular
factor
put
promot
restrict
hcv
replic
human
cell
borawski
et
al
coller
et
al
jone
et
al
li
et
al
ng
et
al
randal
et
al
reiss
et
al
supekova
et
al
tai
et
al
trotard
et
al
vaillancourt
et
al
unfortun
independ
studi
often
minim
overlap
relev
mani
interact
hcv
biolog
remain
demonstr
strong
experiment
evid
provid
critic
role
cyclophilin
cypa
rna
replic
virion
assembl
kaul
et
al
yang
et
al
anoth
essenti
cofactor
rna
replic
independ
identifi
sever
group
borawski
et
al
reiss
et
al
tai
et
al
trotard
et
al
phosphatidylinositol
kinas
iii
recruit
membran
web
via
interact
human
murin
orthologu
cypa
share
high
degre
sequenc
similar
respect
yet
shown
whether
ectop
express
human
cypa
augment
hcv
rna
replic
mous
cell
likewis
littl
evid
accumul
adapt
mutat
boost
viral
rna
replic
mous
cell
foster
effici
interact
mous
orthologu
host
factor
cellular
microrna
drastic
influenc
viru
replic
pathogenesi
gottwein
cullen
liver
specif
microrna
shown
critic
effici
hcv
rna
replic
jopl
et
al
deriv
liverspecif
noncod
polyadenyl
rna
transcrib
gene
hcr
interact
two
site
viral
nontransl
region
ntr
jopl
et
al
jopl
et
al
interact
presum
protect
termin
viral
sequenc
nucleolyt
degrad
induc
innat
immun
respons
rna
terminu
machlin
et
al
result
greater
viral
rna
abund
infect
cultur
cell
liver
infect
chimpanze
lanford
et
al
exact
sequenc
highli
conserv
vertebr
speci
compar
mous
sequencewis
ident
copi
per
hepatocyt
similarli
express
human
counterpart
chang
et
al
consequ
like
contribut
restrict
host
tropism
nonpermiss
speci
possibl
cellintrins
speciesspecif
restrict
factor
similar
control
retrovir
infect
cytidin
deaminas
review
bieniasz
interfer
hcv
rna
replic
murin
cell
howev
heterokaryon
mous
human
cell
capabl
support
hcv
lifecycl
suggest
domin
neg
inhibitor
hcv
replic
exist
frentzen
et
al
differ
magnitud
natur
kinet
antivir
respons
host
known
restrict
tropism
certain
virus
myxoma
viru
permiss
mous
cell
impair
ifn
respons
interferon
system
also
play
pivot
role
limit
hcv
physiolog
condit
trigger
therapeut
intervent
hundr
ifn
stimul
gene
isg
induc
liver
hcv
infect
review
isg
product
potent
inhibit
hcv
infect
fig
pattern
recognit
receptor
prr
tolllik
receptor
tlr
endosom
well
famili
rigi
like
receptor
rlr
includ
retinoicacidinduc
gene
rigi
melanomadifferentiationassoci
gene
sens
presenc
viral
rna
subsequ
host
antivir
respons
activ
result
product
cytokin
type
iii
interferon
yoneyama
et
al
ifn
signal
blunt
hcv
replic
effici
human
hepatoma
cell
blight
et
al
primari
human
hepatocyt
marukian
et
al
similarli
mous
embryon
fibroblast
target
disrupt
protein
kinas
r
pkr
chang
et
al
interferon
regulatori
factor
lin
et
al
rna
replic
enhanc
whether
disrupt
innat
signal
pathway
suffici
render
mice
express
human
hcv
entri
factor
permiss
hcv
infect
yet
shown
hcv
devis
mechan
counteract
innat
defens
may
work
equal
effici
cell
differ
speci
exampl
serin
proteas
essenti
process
hcv
polyprotein
shown
cleav
mitochondri
associ
antivir
signal
protein
mav
meylan
et
al
tcell
protein
tyrosin
phosphatas
tcptp
brenndorf
et
al
tir
domaincontain
adapt
induc
ifn
trif
li
et
al
therebi
modul
antivir
signal
cleavag
motif
mav
trif
partial
conserv
mice
manchimpanze
fig
remain
demonstr
whether
antivir
evas
strategi
function
murin
cell
contrarili
mav
certain
new
world
monkey
speci
includ
rhesu
macaqu
baboon
resist
hcv
infect
function
interferon
signal
even
presenc
heterolog
express
proteas
human
epitheli
cell
thu
escap
hcv
antagon
innat
immun
sens
may
explain
least
part
hcv
speci
restrict
patel
et
al
furthermor
aspect
hcv
antivir
evas
strategi
may
work
less
effici
mous
cell
exampl
shown
inhibit
rlrmediat
ifn
signal
associ
stimul
interferon
gene
sting
nitta
et
al
press
similarli
overexpress
data
suggest
hcv
core
protein
interfer
ifn
signal
downstream
ifn
receptor
presum
direct
interact
lead
reduc
protein
sequenc
mous
human
highli
conserv
sequenc
ident
mous
human
sting
ca
ident
ca
similar
may
result
weaker
interact
murin
orthologu
consequ
exacerb
rlr
signal
develop
infecti
cell
cultur
system
recapitul
part
viral
lifecycl
pave
way
studi
hcv
assembl
egress
releas
increas
evid
point
connect
viral
lifecycl
biogenesi
host
lowdens
lipoprotein
vldl
huang
et
al
merz
et
al
ye
lowdens
viral
particl
detect
sera
patient
use
antibodi
target
lipoproteinassoci
protein
notabl
apolipoprotein
apo
b
e
nielsen
et
al
role
specif
apolipoprotein
virion
assembl
incomplet
understood
loss
function
experi
point
toward
mancon
et
al
apob
huang
et
al
apo
review
bartenschlag
et
al
potenti
player
process
human
cell
function
vldl
pathway
capabl
produc
infecti
hcv
unclear
whether
speci
would
also
support
late
stage
hcv
lifecycl
investig
process
mous
cell
harbor
subgenom
hcv
replicon
transcompl
hcv
core
protein
margin
amount
infecti
hcv
releas
compar
transcriptom
analysi
mous
cell
contain
hcv
replicon
hint
low
level
apo
repliconcontain
cell
might
limit
hcv
assembl
inde
complement
human
mous
apo
suffici
rescu
infecti
hcv
product
cell
yield
infecti
titer
similar
observ
wide
use
human
hepatoma
cell
line
data
confirm
critic
import
apo
hcv
assembl
provid
evid
mous
cell
support
late
stage
hcv
lifecycl
critic
compon
vldl
pathway
present
howev
remain
unclear
whether
hcv
assembl
physiolog
relev
system
importantli
mice
capabl
produc
infecti
particl
vivo
substanti
progress
made
understand
hcv
lifecycl
translat
improv
therapi
experiment
system
devis
studi
hcv
cell
cultur
enabl
compar
studi
elucid
barrier
restrict
hcv
infect
human
chimpanze
murin
cell
engin
express
human
ortholog
entri
molecul
occludin
allow
entri
viral
rna
replic
still
low
cell
least
part
due
vari
antivir
defens
murin
cell
intact
vldl
pathway
produc
infecti
virion
taken
togeth
observ
rais
hope
inbr
mous
model
hcv
infect
achiev
recapitul
entir
viral
lifecycl
mous
would
certainli
great
import
remain
seen
whether
model
would
also
mimic
clinic
relev
diseas
aspect
human
pathogenesi
context
chronic
hcv
infect
thought
driven
persist
liver
inflamm
ultim
result
fibrosi
cirrhosi
liver
cancer
thu
establish
hcv
innat
immun
respons
hcv
infect
ch
chimpanze
dsrna
doublestrand
rna
er
endoplasmat
reticulum
hu
human
ifn
interferon
ifnar
interferonalpha
receptor
il
interleukin
irf
interferon
regulatori
factor
jak
janu
kinas
ms
mous
mav
mitochondri
associ
antivir
signal
protein
melanomadifferentiationassoci
gene
pkr
protein
kinas
r
rh
rhesu
macaqu
rigi
retinoicacidinduc
gene
ssrna
singlestrand
rna
signal
transduc
activ
transcript
signal
transduc
activ
transcript
sting
stimul
interferon
gene
tlr
tolllik
receptor
trif
tirdomaincontain
adapterinduc
interferon
tyk
tyrosin
kinas
inlet
sequenc
align
cleavag
motif
within
mav
differ
permiss
nonpermiss
speci
persist
presenc
function
immun
system
like
necessari
model
adequ
hcv
pathogenesi
studi
character
chronic
human
mice
engraft
human
hepatocyt
compon
human
immun
system
washburn
et
al
well
longterm
follow
studi
tree
shrew
amako
et
al
hint
may
becom
possibl
dissect
liver
diseas
progress
small
anim
model
cours
hcv
infect
studi
great
detail
chimpanze
larg
mirror
adequ
acut
chronic
hcv
infect
human
whether
hcv
infect
speci
inbr
mice
follow
similar
clinic
cours
unclear
howev
even
hcv
infect
caus
eg
mostli
acut
hepat
mice
inherit
trait
render
anim
permiss
hcv
could
combin
genet
background
prone
chronic
liver
diseas
progress
differ
approach
includ
viral
host
adapt
like
need
construct
select
hcv
permiss
anim
model
combin
may
suitabl
replac
chimpanze
costeffect
anim
model
amend
genet
manipul
reproduc
produc
higher
throughput
would
undoubtedli
lend
address
current
intract
problem
hcv
research
